drugset / Trial / NCT04134715

A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants

NCT04134715

Phase 1 Completed 15 enrolled Pfizer
SequentialOpen-labelOther

Summary

This is a Phase 1, fixed sequence, multiple dose, open label study of the effect of PF-06826647 on oral contraceptive (OC) pharmacokinetics (PK) and vice versa in healthy female participants. A total of approximately 15 healthy female participants will be enrolled and dosed to achieve at least 12 participants completing the study.

Timeline

Start
2019-10-23
Primary completion
2020-01-09
Completion
2020-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject EE Unknown 30 ug Oral
Subject LN Unknown 150 ug Oral
Subject ROPSACITINIB Small molecule 600 mg

Indications

No indication recorded.